Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
226.1 USD | -0.10% | -0.22% | -9.73% |
02:53am | Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate | MT |
Mar. 22 | Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 8.76B | |
+73.13% | 12.06B | |
+24.86% | 7.64B | |
-3.97% | 5.56B | |
-7.90% | 4.87B | |
-1.45% | 4.62B | |
+8.48% | 3.94B | |
-24.93% | 2.75B | |
+5.32% | 2.11B | |
+0.26% | 1.89B |
- Stock
- Equities
- Stock Penumbra, Inc. - Nyse
- News Penumbra, Inc.
- Insider Sell: Penumbra